Cargando…

Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers

Despite constituting approximately two thirds of all breast cancers, the luminal A and B tumours are poorly classified at both clinical and molecular levels. There are contradictory reports on the nature of these subtypes: some define them as intrinsic entities, others as a continuum. With the aim o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tishchenko, Inna, Milioli, Heloisa Helena, Riveros, Carlos, Moscato, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920434/
https://www.ncbi.nlm.nih.gov/pubmed/27341628
http://dx.doi.org/10.1371/journal.pone.0158259
_version_ 1782439395115139072
author Tishchenko, Inna
Milioli, Heloisa Helena
Riveros, Carlos
Moscato, Pablo
author_facet Tishchenko, Inna
Milioli, Heloisa Helena
Riveros, Carlos
Moscato, Pablo
author_sort Tishchenko, Inna
collection PubMed
description Despite constituting approximately two thirds of all breast cancers, the luminal A and B tumours are poorly classified at both clinical and molecular levels. There are contradictory reports on the nature of these subtypes: some define them as intrinsic entities, others as a continuum. With the aim of addressing these uncertainties and identifying molecular signatures of patients at risk, we conducted a comprehensive transcriptomic and genomic analysis of 2,425 luminal breast cancer samples. Our results indicate that the separation between the molecular luminal A and B subtypes—per definition—is not associated with intrinsic characteristics evident in the differentiation between other subtypes. Moreover, t-SNE and MST-kNN clustering approaches based on 10,000 probes, associated with luminal tumour initiation and/or development, revealed the close connections between luminal A and B tumours, with no evidence of a clear boundary between them. Thus, we considered all luminal tumours as a single heterogeneous group for analysis purposes. We first stratified luminal tumours into two distinct groups by their HER2 gene cluster co-expression: HER2-amplified luminal and ordinary-luminal. The former group is associated with distinct transcriptomic and genomic profiles, and poor prognosis; it comprises approximately 8% of all luminal cases. For the remaining ordinary-luminal tumours we further identified the molecular signature correlated with disease outcomes, exhibiting an approximately continuous gene expression range from low to high risk. Thus, we employed four virtual quantiles to segregate the groups of patients. The clinico-pathological characteristics and ratios of genomic aberrations are concordant with the variations in gene expression profiles, hinting at a progressive staging. The comparison with the current separation into luminal A and B subtypes revealed a substantially improved survival stratification. Concluding, we suggest a review of the definition of luminal A and B subtypes. A proposition for a revisited delineation is provided in this study.
format Online
Article
Text
id pubmed-4920434
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49204342016-07-18 Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers Tishchenko, Inna Milioli, Heloisa Helena Riveros, Carlos Moscato, Pablo PLoS One Research Article Despite constituting approximately two thirds of all breast cancers, the luminal A and B tumours are poorly classified at both clinical and molecular levels. There are contradictory reports on the nature of these subtypes: some define them as intrinsic entities, others as a continuum. With the aim of addressing these uncertainties and identifying molecular signatures of patients at risk, we conducted a comprehensive transcriptomic and genomic analysis of 2,425 luminal breast cancer samples. Our results indicate that the separation between the molecular luminal A and B subtypes—per definition—is not associated with intrinsic characteristics evident in the differentiation between other subtypes. Moreover, t-SNE and MST-kNN clustering approaches based on 10,000 probes, associated with luminal tumour initiation and/or development, revealed the close connections between luminal A and B tumours, with no evidence of a clear boundary between them. Thus, we considered all luminal tumours as a single heterogeneous group for analysis purposes. We first stratified luminal tumours into two distinct groups by their HER2 gene cluster co-expression: HER2-amplified luminal and ordinary-luminal. The former group is associated with distinct transcriptomic and genomic profiles, and poor prognosis; it comprises approximately 8% of all luminal cases. For the remaining ordinary-luminal tumours we further identified the molecular signature correlated with disease outcomes, exhibiting an approximately continuous gene expression range from low to high risk. Thus, we employed four virtual quantiles to segregate the groups of patients. The clinico-pathological characteristics and ratios of genomic aberrations are concordant with the variations in gene expression profiles, hinting at a progressive staging. The comparison with the current separation into luminal A and B subtypes revealed a substantially improved survival stratification. Concluding, we suggest a review of the definition of luminal A and B subtypes. A proposition for a revisited delineation is provided in this study. Public Library of Science 2016-06-24 /pmc/articles/PMC4920434/ /pubmed/27341628 http://dx.doi.org/10.1371/journal.pone.0158259 Text en © 2016 Tishchenko et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Tishchenko, Inna
Milioli, Heloisa Helena
Riveros, Carlos
Moscato, Pablo
Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers
title Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers
title_full Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers
title_fullStr Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers
title_full_unstemmed Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers
title_short Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers
title_sort extensive transcriptomic and genomic analysis provides new insights about luminal breast cancers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920434/
https://www.ncbi.nlm.nih.gov/pubmed/27341628
http://dx.doi.org/10.1371/journal.pone.0158259
work_keys_str_mv AT tishchenkoinna extensivetranscriptomicandgenomicanalysisprovidesnewinsightsaboutluminalbreastcancers
AT milioliheloisahelena extensivetranscriptomicandgenomicanalysisprovidesnewinsightsaboutluminalbreastcancers
AT riveroscarlos extensivetranscriptomicandgenomicanalysisprovidesnewinsightsaboutluminalbreastcancers
AT moscatopablo extensivetranscriptomicandgenomicanalysisprovidesnewinsightsaboutluminalbreastcancers